<SEC-DOCUMENT>0001564590-21-029081.txt : 20210520
<SEC-HEADER>0001564590-21-029081.hdr.sgml : 20210520
<ACCEPTANCE-DATETIME>20210520162227
ACCESSION NUMBER:		0001564590-21-029081
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210520
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210520
DATE AS OF CHANGE:		20210520

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			C4 Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001662579
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475617627
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39567
		FILM NUMBER:		21944800

	BUSINESS ADDRESS:	
		STREET 1:		490 ARSENAL WAY
		STREET 2:		SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
		BUSINESS PHONE:		(617) 231-0700

	MAIL ADDRESS:	
		STREET 1:		490 ARSENAL WAY
		STREET 2:		SUITE 200
		CITY:			WATERTOWN
		STATE:			MA
		ZIP:			02472
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cccc-8k_20210520.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-8k_20210520.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;border-top:Double 2.25pt;padding-top:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): May 20, 2021</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C4 THERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">001-39567</p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">47-5617627</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">490 Arsenal Way, Suite 200</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Watertown, MA</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;line-height:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">02472</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;line-height:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (617) 231-0700 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td>
</tr>
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Common Stock, $0.0001 par value per share</font></p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CCCC</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Global Select Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:Segoe UI Symbol;font-size:11pt;">&#9746;</font></p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Appointment of Chief Financial Officer, Treasurer, Principal Financial Officer and Principal Accounting Officer</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 20, 2021, C4 Therapeutics, Inc. (the &#8220;<font style="font-weight:bold;">Company</font>&#8221; or &#8220;<font style="font-weight:bold;">us</font>&#8221;), announced the appointment of Lauren White as its Chief Financial Officer and treasurer, effective as of June 21, 2021. Ms. White will also serve as the Company&#8217;s principal financial officer and principal accounting officer effective as of such date.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms. White, age 42, joins the Company with over 20 years of international experience in corporate finance and strategy. She is joining from Novartis where, since 2017, she held roles of increasing responsibility within the global finance organization. Most recently, she served as vice president and global head of business planning and analysis at Novartis Institutes for BioMedical Research (NIBR), where she led strategic financial projects for the global research unit. At Novartis, Ms. White also launched the global health business unit as chief financial officer after serving in roles across global finance and financial reporting and accounting. Prior to Novartis, Ms. White worked from 2006 to 2011 in strategy and marketing roles with Boston Consulting Group and from 2000 to 2005 with General Electric. Ms. White earned an M.B.A. from Harvard Business School in 2007 and a B.S. from the Carroll School of Management at Boston College in 2000.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with Ms. White&#8217;s appointment, she will receive an annual base salary of $415,000, a sign-on bonus of $60,000 and an opportunity to earn a performance bonus of up to 40% of her base salary per year. She will also receive an option to purchase up to 136,000 shares of the Company&#8217;s common stock at the exercise price equal to the last reported price of the Company&#8217;s stock on the Nasdaq Stock Market on the effective date of her commencement of employment, such stock option to vest in equal monthly installments over a period of four years with a one-year cliff. She will also enter into an employment agreement with the Company in substantially the form filed as Exhibit 10.7 to the Company&#8217;s registration statement on Form S-1 on September 10, 2020 (the &#8220;<font style="font-weight:bold;">Registration Statement</font>&#8221;), which is incorporated herein by reference, and an indemnification agreement with the Company in substantially the form filed as Exhibit 10.6 to the Registration Statement, which is also incorporated herein by reference. </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to provide for the orderly transition of Ms. White&#8217;s responsibilities, William T. McKee, the Company&#8217;s current Chief Financial Officer, has agreed to remain with the Company as a consultant to Ms. White and the Company on an as needed basis until July 2, 2021.</p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">There are no family relationships between Ms.&#160;White and any of the Company&#8217;s directors or executive officers. In addition, Ms.&#160;White is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item&#160;404(a)&#160;of&#160;Regulation S-K.</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company issued a press release on May 20, 2021 announcing Ms. White&#8217;s appointment. The press release is attached hereto as Exhibit 99.1. Pursuant to General Instruction B.2. to Form 8-K, the information set forth in Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Interim Appointment of Principal Accounting Officer</font></p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As announced on April 30, 2021, the Company&#8217;s VP, Finance and Corporate Controller and principal accounting officer, Laura J. Wahlberg, resigned from her employment with the Company, effective as of May 28, 2021. Upon Ms. Wahlberg&#8217;s departure, Mr. McKee will assume the role of the Company&#8217;s principal accounting officer on an interim basis and will serve in that capacity until Ms. White assumes that role upon the commencement of her employment with the Company.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. McKee, age 59, has served as our Chief Financial Officer since April 2020 and, since February 2021, as our corporate Treasurer. Mr. McKee has also served as Chief Executive Officer of MBJC Associates, LLC, a business consulting firm serving pharmaceutical and biotechnology companies, since February 2010. Mr. McKee served as Chief Operating Officer and Chief Financial Officer of EKR Therapeutics, Inc., from July 2010 to June 2012, when EKR was sold to Cornerstone Therapeutics Inc., a pharmaceutical company. From January 2009 to March 2010, Mr. McKee served as the Executive Vice President, Chief Financial Officer and Treasurer of Barr Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceutical Industries Limited (NYSE: TEVA), or Teva. Mr. McKee was also Executive Vice President and Chief Financial Officer of Barr prior to its acquisition by Teva, having joined the company in 1995. Mr. McKee has served as a director and chairman of the audit committee and member of the compensation committee of Assertio Therapeutics, Inc. (Nasdaq: ASRT), a specialty pharmaceutical company, since March 2017, and has served as a director and chairman of the audit committee of Aileron Therapeutics, Inc. (Nasdaq: ALRN), a biopharmaceutical company, since March 2019. Mr. McKee also serves as a director of Vinci Pharmaceuticals, Inc., a biotechnology company developing specialty ophthalmic products for the retina, since June 2020. Mr. McKee holds a B.B.A. from the University of Notre Dame.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. McKee provides services to us as our Chief Financial Officer under a consulting agreement, dated March 31, 2020, with MBJC Associates, LLC, a copy of which was filed as Exhibit 10.9 to the Registration Statement and is incorporated herein by reference.</p>
<p style="margin-bottom:12pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01 Financial Statements and Exhibits.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;<font style="text-decoration:underline;">Exhibits</font>. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="color:#000000;">99.1</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cccc-ex991_8.htm"><font style="text-decoration:underline;">Press Released dated May 20, 2021 (furnished herewith)</font></a></p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 20, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jolie M. Siegel</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jolie M. Siegel</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legel Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cccc-ex991_8.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cccc-ex991_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvcq5lipu0sf000001.jpg" title="" alt="" style="width:178px;height:41px;"><font style="font-weight:bold;font-size:11pt;">C4 Therapeutics Appoints Lauren White as Chief Financial Officer</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WATERTOWN, Mass., May 20, 2021 (GLOBE NEWSWIRE) &#8211; C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the appointment of Lauren White to the role of chief financial officer, effective June 21, 2021. Ms. White&#8217;s appointment will initiate William (Bill) McKee&#8217;s planned transition from interim chief financial officer, a role he has held since March 31, 2020. Mr. McKee will remain engaged to support C4T in a part-time consulting capacity to ensure a smooth transition. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;As we continue to advance our portfolio of novel protein degraders, we are delighted to welcome Lauren to our team. Her proven track record of strategically allocating resources across research and early-stage clinical development programs, as well as her experiences in financial reporting and accounting, will be invaluable as we continue to build C4T and work to transform patient care,&#8221; said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. &#8220;In addition, we are incredibly grateful for Bill&#8217;s contributions in shepherding C4T through our Series B financing and initial public offering and in establishing a foundational financial framework for C4T as a public company.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms. White joins C4 Therapeutics with over 20 years of international experience in corporate finance and strategy. She is joining from Novartis, where she held roles of increasing responsibility within the global finance organization. Most recently, she served as vice president and global head of business planning and analysis at Novartis Institutes for BioMedical Research (NIBR), where she led strategic financial projects for the global research unit. At Novartis, Ms. White also launched the global health business unit as chief financial officer after serving in roles across global finance and financial reporting and accounting. Earlier in her career, Ms. White worked in strategy and marketing roles with Boston Consulting Group and General Electric. Ms. White earned an M.B.A. from Harvard Business School and a B.S. from the Carroll School of Management at Boston College.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;I am thrilled to join C4 Therapeutics at a pivotal time in the Company&#8217;s development, as it prepares to initiate its first clinical trial and advance a novel portfolio of targeted protein degraders for the benefit of patients,&#8221; said Ms. White. &#8220;Targeted protein degradation offers distinct advantages over traditional small molecule approaches and I believe C4T&#8217;s powerful drug discovery engine has immense potential across a range of oncology indications. I look forward to working with the team towards our shared mission of transforming patient treatment through targeted protein degradation.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About C4 Therapeutics</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body&#8217;s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit <font style="text-decoration:underline;">www.C4Therapeutics.com</font>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains &#8220;forward-looking statements&#8221; of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy of our therapeutic approaches; the predictive capability of our TORPEDO&#8482; platform in the development of novel, selective, orally bioavailable degraders; the </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for regulatory authorization related to clinical trials; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our current resources and cash runway; and regulatory developments in the United States and foreign countries. Any forward-looking statements in this press release are based on management&#8217;s current expectations and beliefs of future events and are subject to </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of preclinical and clinical studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will cost more to develop or may not be successfully developed and commercialized; and the risk that the results of preclinical studies and/or clinical trials will or will not be predictive of future results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled &#8220;Risk Factors&#8221; in C4 Therapeutics&#8217; most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Investor Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kendra Adams</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SVP, Communications &amp; Investor Relations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Kendra.Adams@c4therapeutics.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Media Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loraine Spreen</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director, Corporate Communications &amp; Patient Advocacy</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">lspreen@c4therapeutics.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gvcq5lipu0sf000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvcq5lipu0sf000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? 9D# 2(  A$! Q$!_\0
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MI+&Q1U/52#@BF5ZYXS^'[:K<-J6DF-+I@3-"QPLIQU4]F/3G@]<CG/#_ /"
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M?X5R^K_\)3\09;?3SHCZ58Q2"1WN01AL$9R0">"> .IY/IJ_\*AT3_G\O_\
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MZP?^U*]3K-TK0-+T0S'3;1;<S8\S:Q.[&<=3[FM*AB6P4444#"BBB@ HHHH
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3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
